medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2013, Number 6

<< Back Next >>

Acta Pediatr Mex 2013; 34 (6)

Intravenous gammaglobulin for the treatment of juvenile idiopathic arthritis

López-Ortiz DJ, Gutiérrez-Hernández JA

Language: Spanish
References: 30
Page: 364-369
PDF size: 337.31 Kb.


ABSTRACT

Recently there has been a growing interest in autoimmune and auto-inflammatory diseases, both entities involving a therapeutic challenge even though more sophisticated therapeutic options have been developed. According to this, juvenile idiopathic arthritis (JIA) is an example of this challenge, with proven autoimmune mechanisms as in positive rheumatoid factor arthritis; and autoinflammatory mechanisms in systemic onset juvenile idiopathic arthritis. For both damage mechanisms, intravenous immunoglobulin (IVIG) has been used as a successful immunomodulator. The treatment with IVIG for JIA and associated features as macrophage activation syndrome (MAS) has shown to be beneficial. Nevertheless more studies are required to support its usefulness, as well as clinical trials to document the IVIG effectiveness in comparison with the rest of therapeutic agents used. Despite its cost, the IVIG is well tolerated and should be considered useful in combination with other drugs as part of the JIA treatment, especially in those patients with associated threatening-life systemic complications or with high risk of infection. The present review pretends to expose, according to previous references from various authors, that IVIG is an alternative therapeutic option in these cases.


REFERENCES

  1. Laufer TM. Inflammatory arthritis-an exciting confluence of human and animal research. Immunol Rev. 2010;233:5-8.

  2. Weiss J, Ilowite N. Juvenile idiopathic artritis. Pediatr Clin North Am. 2005;52 (2):413-442.

  3. Gare BA. Juvenile arthritis-who gets it where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol. 1999;17:367-374.

  4. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second review. Edmonton, 2001. J Rheumatol. 2004;31(2):390-392.

  5. Ramsey S, Cabral D. Comparison of criteria for the classification of childhood arthritis. J Rheumatol. 2000;27:1283-1286.

  6. Foeldvari I. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. J Rheumatol. 2000;27:1069-1072.

  7. Beukelman T, Patkar N, Saag K, Tolleson-Rinehart S, Cron R, Dewitt E, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care & Res. 2011;63(4):465-482.

  8. Yokota S, Mori M, Takei T, Imagawa T, Murata T, Tomiita M, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists. Mod Rheumatol. 2007;17:353-356.

  9. Ministerio de Salud de Chile. Artritis Idiopática Juvenil/Guía Clínica Artritis Reumatoide Juvenil. Santiago. MINSAL. 2010. http://www.minsal.gob.cl/portal/url/item/955578f799fcef2ae04 001011f01678a.pdf

  10. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421-426.

  11. Singh S, Chandrakasan S, Ahluwalia J, Suri D, Rawat A, Ahmed N. Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India. Rheumatol Int. 2012;32:881-886.

  12. Tristano A, Casanova-Escalona L, Torres A, Rodríguez MA. Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis. J Clin Rheumatol. 2003;9:253-258.

  13. Deane S, Selmi C, Teuber SS, Gershwin ME. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol. 2010;153:109-120.

  14. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106:561-566.

  15. Hull R. Guidelines for management of childhood arthritis. Rheumatology. 2001;40:1309-1312.

  16. Vaitla P, McDermott EM. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology. 2010;49:1040-1048.

  17. Kahn P. Juvenile idiopathic arthritis: an update on pharmacology. Bull NYU Hosp Jt Dis. 2011;69(3):264-276.

  18. Bayry J. Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:349-359.

  19. Muscat C, Bertotto A, Ercolani R, Bistoni O, Agea E, Cesarotti M, et al. Long-term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulin: effects on disease activity and serum cytokines. Ann Rheum Dis. 1995;54:382-385.

  20. Silverman E, Laxer RM, Greenwald M, Gelfand E, Shore A, Stein LD, et al. Intravenous gammaglobulin therapy in systemic juvenile rheumatoid arthritis. Arthr Rheum. 1990;33(7):1015- 1022.

  21. Bagge E, Tarkowski A. Intra-articular administration of polyclonal immunoglobulin G in rheumatoid arthritis. Scand J Rheumatol. 1996;25:174-176.

  22. Orellana JC, Pogonza RE, López-Olivo MA, Roundtree AK, Ortiz Z. Intravenous immunoglobulin for juvenile idiopathic arthritis (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006191. DOI: 10.1002/14651858. CD006191.

  23. Tumiati B, Casoli P, Veneziani M, Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthr Rheum. 1992;35:1126-1133.

  24. Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic disease. Rheumatology. 2002;41:367-374.

  25. Kanik KS, Yarboro CH, Naparstek Y, Plotz PH, Wilder RL. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthr Rheum. 1996;39:1027-1029.

  26. Maeda H, Furonaka O, Matsushima K, Awaya Y, Kuwabara M. Successful treatment of “malignant rheumatoid arthritis in Japan with pooled intravenous immunoglobulin” (Letters to the Editor). Rheumatology. 2001;40:955-956.

  27. Uzeil Y, Laxer RM, Schneider R, Silverman ED. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study. J Rheumatol 1996;23:910-918.

  28. Aizawa-Yashiro T. Oki E, Tsuruga K, Nakahata T, Ito E, Tanaka H. Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy. Rheumatol Int. 2012;32:1359-1361.

  29. Silverman ED, Cawkwell GD, Lovell DJ, Laxer RM, Lehman TJ, Passo MH, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994; 21(12): 2353-2358.

  30. Prieur AM, Adleff A, Debre M, Boulate P, Griscelli C. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol 1990;8:603-608.




2020     |     www.medigraphic.com